Designing poly(gamma-aminobutyric acid)-based nanoparticles for the treatment of major depressive disorders.
Level 5 - mechanism / opinion, no new human data
Preclinical in vitro formulation and animal model study
PubMed 37336293 · doi:10.1016/j.jconrel.2023.06.021
What was done
Researchers developed an aqueous, orally deliverable nanoparticle formulation (Nano_GABA) composed of amphiphilic diblock copolymers of poly(gamma-aminobutyric acid) and poly(ethylene glycol) to address the poor solubility and pharmacokinetic clearance of conventional GABA and poly(GABA). The therapeutic efficacy of oral Nano_GABA was evaluated in mouse models of depression using behavioral paradigms (forced swimming tests and tail suspension tests) and quantification of the stress biomarker corticosterone.
What was found
Oral administration of Nano_GABA attenuated depression-like behaviors in forced swimming and tail suspension tests and reduced corticosterone levels in the mouse depression model. The abstract did not report specific numerical values, sample sizes, or effect sizes.
Why it matters
This study provides proof-of-concept for an orally stable poly(GABA) nanoparticle delivery platform that targets the gut-brain axis, potentially overcoming the blood-brain barrier permeability and rapid gastrointestinal degradation limits of free GABA.
Limits
Findings are limited to preclinical mouse models and cannot be directly translated to human major depressive disorder without clinical trials. The abstract omits sample sizes (n), dosage regimens, exact quantitative measurements, and confidence intervals. Rodent behavioral assays provide only an indirect proxy for human depressive pathology.
Cited by
- supports GABA produced in the gut does not cross the blood-brain barrier.